Cargando…
Comparative Molecular Characterization and Pharmacokinetics of IgG1-Fc and Engineered Fc Human Antibody Variants to Insulin-like Growth Factor 2 Receptor (IGF2R)
Novel therapeutic approaches are much needed for the treatment of osteosarcoma. Targeted radionuclide therapy (TRT) and radioimmunotherapy (RIT) are promising approaches that deliver therapeutic radiation precisely to the tumor site. We have previously developed a fully human antibody, named IF3, th...
Autores principales: | Prabaharan, Chandra B., Giri, Sabeena, Allen, Kevin J. H., Bato, Katrina E. M., Mercado, Therese R., Malo, Mackenzie E., Carvalho, Jorge L. C., Dadachova, Ekaterina, Uppalapati, Maruti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420659/ https://www.ncbi.nlm.nih.gov/pubmed/37570809 http://dx.doi.org/10.3390/molecules28155839 |
Ejemplares similares
-
Novel Human Antibodies to Insulin Growth Factor 2 Receptor (IGF2R) for Radioimmunoimaging and Therapy of Canine and Human Osteosarcoma
por: Broqueza, Jaline, et al.
Publicado: (2021) -
Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models
por: Broqueza, Jaline, et al.
Publicado: (2021) -
Pharmacokinetic Models for FcRn-Mediated IgG Disposition
por: Xiao, Jim J.
Publicado: (2012) -
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye
por: Kim, Hyuncheol, et al.
Publicado: (2009) -
Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics
por: Piche-Nicholas, Nicole M., et al.
Publicado: (2017)